Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Effect of probiotic supplementation on plasma metabolite profile after Roux-Y gastric bypass: a prospective, randomized, double-blind, placebo-controlled clinical trial.

  • 2022-08-20
  • International journal of obesity (2005) 46(11)
    • Marília Rizzon Zaparolli Ramos
    • Ingrid Felicidade
    • Lígia de Oliveira Carlos
    • Nathalia Ramori Farinha Wagner
    • Mário Sérgio Mantovani
    • Luan Vitor Alves de Lima
    • Lúcia Regina Ribeiro
    • Thiago Inácio Barros Lopes
    • Fernanda Carla Henrique-Bana
    • João Vitor Zimmerman
    • Fernando Cesar Macedo Junior
    • Magda Rosa Ramos da Cruz
    • Antônio Carlos Ligocki Campos

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 31
Population
31 patients subjected to RYGB surgery
Methods
randomized, double-blind, placebo-controlled clinical trial; probiotic group supplemented with a probiotic supplement (FloraVantage®) for 3 months after surgery or a placebo group; plasma metabonomics using NMR
Blinding
Double-blind
Duration
3 months

Background/objective

There is evidence that metabolic profile changes after Roux-Y gastric bypass (RYGB), especially due to modifications in the gastrointestinal tract. In addition, previous studies have suggested that probiotics can modify the microbiome and produce metabolites important for metabolic health maintenance. In this sense, the aim of this study was to verify the influence of probiotic supplementation on the plasma metabolite profile after RYGB.

Methods

This was a randomized, double-blind, placebo-controlled clinical trial conducted with 31 patients subjected to RYGB surgery, randomized in probiotic group that was supplemented with a probiotic supplement (FloraVantage®) for 3 months after surgery or a placebo group. Plasma metabonomics was performed using nuclear magnetic resonance (NMR) at the preoperative period (T0) and at 45-50 days (T1) and 90-95 days (T2) during the postoperative period/intervention.

Results

Reductions in trimethylamine-N-oxide (TMAO) and alanine were observed in both groups, however this reduction was greater in the probiotic group (TMAO 13.82%, p = 0.01 and alanine 14.03%, p = 0.03) at T2. Additionally, β-hydroxybutyrate (BHB) levels increased 10.77% in the probiotic group (p = 0.03) compared to the placebo group at T2.

Conclusion

Supplementation with Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 was able to associate with significant differences in relevant plasma metabolites associated with improved metabolic health.

Research Insights

    Back to top